Is Hims & Hers Health a Smart Buy Right Now?

Hims & Hers Health (HIMS) has seen its stock price surge 157% in the last 12 months, driven by a 38% year-over-year increase in subscribers and a 111% revenue jump in the recent quarter, fueled by its telemedicine platform and subscription model. Despite this growth and investments in AI, Wall Street analysts remain largely neutral or bearish on the stock, with an average price target implying a 12% downside; the stock's rally may be fueled by a high and rising short interest (35% of float), creating potential for a short squeeze and increased volatility, leading to caution about its long-term investment potential.

Analysis

Hims & Hers Health (NYSE: HIMS) has demonstrated remarkable growth, with its shares surging 157% over the past 12 months as of June 4th, driven by strong operational performance. In the first quarter, the telemedicine company reported a 38% year-over-year increase in subscribers to 2.4 million, which propelled revenue to $586 million, a 111% year-over-year increase. This growth is underpinned by its subscription-based model offering medications for various conditions, benefiting from recurring revenue and high gross margins, and allowing for reinvestment into areas like AI to analyze customer data for further expansion. Despite these impressive metrics and strategic investments in technology, Wall Street sentiment remains notably cautious. Major equity research analysts from firms including Piper Sandler, Citigroup, Bank of America, and Morgan Stanley have maintained neutral, sell, underperform, or equal-weight ratings. The consensus analyst price target of approximately $48 suggests a potential 12% downside from early June trading levels. A significant factor potentially influencing the stock's rally is its high and rising short interest, which stands at roughly 35% of the float. This elevated short interest could be fueling volatility and price increases due to short covering activity, characteristic of a short squeeze, rather than purely fundamental conviction, leading to concerns about the sustainability of the current valuation and stock behavior resembling that of a 'meme stock'.

Key Decisions for Investors

• Investors should acknowledge Hims & Hers' exceptional revenue and subscriber growth but remain cognizant of the substantial stock price appreciation, which may be partly driven by short squeeze dynamics rather than solely by fundamentals.
• Given the high short interest (35% of float) and the associated potential for significant price volatility, positions in HIMS carry an elevated risk profile that warrants careful monitoring.
• Consider the divergence between the company's strong reported growth and the predominantly neutral-to-bearish stance from Wall Street analysts, whose average price target implies potential downside, before initiating or expanding positions.
• Evaluate whether the investment thesis aligns with a long-term strategy, as the current stock dynamics, as highlighted in the analysis, suggest it may be more suited for traders comfortable with high volatility and speculative elements rather than conservative, long-term investors at its present valuation.